ALBT's Net Loss Soars to $15.9M Amid Debt Extinguishment, Cash Dwindles

TL;DR

**ALBT is burning cash and drowning in debt, making it a high-risk bet despite minor revenue gains.**

AI Summary

Avalon GloboCare Corp. (ALBT) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $15,940,709, a substantial rise from $3,499,539 in the prior year. This was primarily driven by a $9,076,587 loss on extinguishment of debt and a new $1,650,000 credit loss expense. Revenue from real property rental saw a modest increase to $700,206 for the six months ended June 30, 2025, up from $642,475 in the same period of 2024. Operating income from real property also improved to $168,739 from $93,861. However, total current assets plummeted from $3,236,498 at December 31, 2024, to $933,088 at June 30, 2025, largely due to a decrease in cash from $2,856,309 to $201,532. The company redeemed its 40% equity interest in Lab Services MSO to preserve cash and issued Series D Convertible Preferred Stock valued at $8,837,527. Total liabilities increased to $15,100,429 from $13,882,555, while total equity shifted from a positive $7,102,623 to a deficit of $(7,112,273).

Why It Matters

Avalon GloboCare's substantial net loss and dwindling cash reserves signal significant financial distress, raising red flags for investors. The company's strategic shift to redeem its Lab Services MSO equity to preserve cash, while prudent, highlights underlying liquidity challenges. This financial instability could impact ALBT's ability to fund its precision diagnostic and cellular therapy intellectual property advancements, potentially hindering its competitive position against larger, better-capitalized biotech firms. Employees may face job insecurity, and customers could see disruptions in product development or service availability if the company's financial health does not improve, impacting the broader market's confidence in small-cap biotech ventures.

Risk Assessment

Risk Level: high — The company's cash balance decreased from $2,856,309 at December 31, 2024, to $201,532 at June 30, 2025, representing a 93% decline. Total liabilities increased to $15,100,429, while total equity swung to a deficit of $(7,112,273) from a positive $7,102,623, indicating severe financial instability and a negative net worth.

Analyst Insight

Investors should avoid ALBT given its rapidly deteriorating financial position, marked by a significant net loss, declining cash, and a negative equity balance. Existing shareholders should consider divesting to mitigate further losses, as the company's ability to sustain operations and fund future growth is highly questionable.

Financial Highlights

debt To Equity

N/A

revenue

$700,206

operating Margin

24.1%

total Assets

$7,988,156

total Debt

$15,100,429

net Income

-$15,940,709

eps

N/A

gross Margin

N/A

cash Position

$201,532

revenue Growth

+9.0%

Revenue Breakdown

Key Numbers

• $15,940,709 — Net Loss (for the six months ended June 30, 2025, up from $3,499,539 in 2024)
• $9,076,587 — Loss on extinguishment of debt (contributed to the increased net loss)
• $1,650,000 — Credit loss expense (new expense for the six months ended June 30, 2025)
• $201,532 — Cash (at June 30, 2025, down from $2,856,309 at December 31, 2024)
• $7,112,273 — Total (Deficit) Equity (at June 30, 2025, a decrease from $7,102,623 at December 31, 2024)
• $15,100,429 — Total Liabilities (at June 30, 2025, up from $13,882,555 at December 31, 2024)
• $700,206 — Real Property Rental Revenue (for the six months ended June 30, 2025, up from $642,475 in 2024)
• $8,837,527 — Series D Convertible Preferred Stock (issued at June 30, 2025)

Key Players & Entities

• Avalon GloboCare Corp. (company) — registrant
• ALBT (company) — ticker symbol
• Lab Services MSO, LLC (company) — equity method investment redeemed
• Qi Diagnostics Limited (company) — manufacturer of KetoAir breathalyzer
• U.S. Food and Drug Administration (regulator) — KetoAir TM Class I medical device registration
• Avalon RT 9 Properties, LLC (company) — owns and operates real estate
• Arbele Biotherapeutics Limited (company) — 40% owner of Avactis Biosciences Inc.
• The Nasdaq Capital Market (regulator) — exchange where common stock is registered

FAQ

Risk Factors

• Deteriorating Equity Position [high — financial]: The company's total equity has shifted from a positive $7,102,623 at December 31, 2024, to a deficit of $(7,112,273) at June 30, 2025. This significant decline is primarily driven by substantial net losses and the extinguishment of debt.
• Severe Cash Burn [high — financial]: Total current assets have plummeted from $3,236,498 to $933,088, with cash decreasing from $2,856,309 to $201,532 in six months. This indicates a rapid depletion of liquid assets, raising concerns about ongoing operational funding.
• Increased Indebtedness [medium — financial]: Total liabilities have risen to $15,100,429 from $13,882,555. The company has also issued Series D Convertible Preferred Stock valued at $8,837,527, which, while potentially providing capital, adds to future dilution or debt obligations.
• Significant Loss on Debt Extinguishment [medium — operational]: A substantial loss of $9,076,587 on the extinguishment of debt significantly contributed to the increased net loss of $15,940,709 for the six months ended June 30, 2025. This suggests costly debt restructuring or early repayment activities.
• New Credit Loss Expense [medium — financial]: The company incurred a new credit loss expense of $1,650,000 for the six months ended June 30, 2025. This indicates potential issues with the collectibility of receivables or other credit exposures.
• Divestiture of Equity Investment [low — operational]: Avalon GloboCare redeemed its 40% equity interest in Lab Services MSO to preserve cash. While this may have immediate liquidity benefits, it signifies a reduction in strategic assets and potential future earnings.

Industry Context

Avalon GloboCare Corp. operates in the healthcare sector, which is characterized by rapid technological advancements, stringent regulatory oversight, and significant competition. Companies in this space often require substantial capital for research, development, and market penetration. The current environment may see increased pressure on healthcare providers and related service companies due to evolving reimbursement policies and economic conditions.

Regulatory Implications

The company's financial distress and significant debt load could attract increased scrutiny from regulatory bodies, particularly concerning its ability to meet ongoing obligations and compliance requirements. Any new financing or restructuring activities will need to adhere to securities regulations and disclosure requirements.

What Investors Should Do

1. Monitor cash burn rate closely.
2. Analyze the impact of Series D Preferred Stock.
3. Evaluate the sustainability of real property rental income.
4. Investigate the reasons for debt extinguishment loss.
5. Assess the implications of the equity deficit.

Key Dates

• 2025-06-30: End of Six-Month Period — Reporting period for the significant increase in net loss, decrease in cash, and shift to a deficit in equity.
• 2025-06-30: Issuance of Series D Convertible Preferred Stock — Raised $8,837,527, impacting the equity structure and potentially future dilution.
• 2025-06-30: Redemption of Lab Services MSO Equity — Strategic decision to preserve cash, reducing the company's asset base.
• 2024-12-31: End of Fiscal Year — Prior period comparative balance sheet data, showing a positive equity position and higher cash reserves.

Glossary

Loss on extinguishment of debt

A loss recognized when a company repays or retires debt before its scheduled maturity date, often due to unfavorable market conditions or refinancing at a higher cost. (A major contributor to the company's increased net loss in the current period.)

Credit loss expense

An expense recognized for potential losses on financial assets, such as loans or accounts receivable, due to a borrower's or counterparty's inability to meet their contractual obligations. (A new expense item impacting the company's profitability in the current period.)

Series D Convertible Preferred Stock

A class of preferred stock that can be converted into a predetermined number of common shares. It often carries specific rights and preferences over common stock. (Represents a significant capital raise but also potential future dilution for common shareholders.)

Equity method investments

An accounting method used to report investments in which the investor has significant influence over the investee. The investment is adjusted for the investor's share of the investee's net income or loss. (The company has eliminated this category, indicating a divestiture or write-off of such investments.)

Deficit Equity

Occurs when a company's total liabilities exceed its total assets, resulting in a negative equity balance. (Indicates the company's precarious financial position, with liabilities outweighing assets.)

Year-Over-Year Comparison

Compared to the prior year's six-month period, Avalon GloboCare Corp. has experienced a dramatic increase in its net loss, soaring from $3,499,539 to $15,940,709. This deterioration is largely attributed to a significant loss on debt extinguishment and a new credit loss expense. While real property rental revenue saw a modest increase of 9.0%, this was overshadowed by the escalating operational and financial costs. The company's balance sheet reflects a severe liquidity crunch, with cash reserves plummeting and total equity shifting into a deficit, indicating a substantially weakened financial position.

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share ALBT The Nasdaq Capital Marke

Filing Documents

• ea0252572-10q_avalon.htm (10-Q) — 1652KB
• ea025257201ex31-1_avalon.htm (EX-31.1) — 11KB
• ea025257201ex31-2_avalon.htm (EX-31.2) — 11KB
• ea025257201ex32-1_avalon.htm (EX-32.1) — 3KB
• ea025257201ex32-2_avalon.htm (EX-32.2) — 4KB
• 0001213900-25-076784.txt ( ) — 8918KB
• avco-20250630.xsd (EX-101.SCH) — 74KB
• avco-20250630_cal.xml (EX-101.CAL) — 55KB
• avco-20250630_def.xml (EX-101.DEF) — 432KB
• avco-20250630_lab.xml (EX-101.LAB) — 702KB
• avco-20250630_pre.xml (EX-101.PRE) — 452KB
• ea0252572-10q_avalon_htm.xml (XML) — 1039KB

– Financial Information

Part I – Financial Information 1

Financial Statements

Item 1. Financial Statements 1 Condensed Consolidated Balance Sheets – At June 30, 2025 (Unaudited) and December 31, 2024 1 Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) – For the Three and Six Months Ended June 30, 2025 and 2024 2 Condensed Consolidated Statements of Changes in (Deficit) Equity (Unaudited) — For the Three and Six Months Ended June 30, 2025 and 2024 3 Condensed Consolidated Statements of Cash Flows (Unaudited) – For the Six Months Ended June 30, 2025 and 2024 5 Notes to Unaudited Condensed Consolidated Financial Statements 6

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 36

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 44

Controls and Procedures

Item 4. Controls and Procedures 45 Part II – Other Information 46

Legal Proceedings

Item 1. Legal Proceedings 46

Risk Factors

Item 1A. Risk Factors 46 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 46 Item 3. Defaults Upon Senior Securities 47

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 47

Other Information

Item 5. Other Information 47 Item 6. Exhibits 47 Exhibit Index 47

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. AVALON GLOBOCARE CORP. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS June 30, December 31, 2025 2024 (Unaudited) ASSETS CURRENT ASSETS: Cash $ 201,532 $ 2,856,309 Rent receivable 84,893 80,829 Prepaid expense and other current assets 646,663 299,360 Total Current Assets 933,088 3,236,498 NON-CURRENT ASSETS: Operating lease right-of-use assets, net 98,595 4,709 Property and equipment, net 8,512 12,912 Investment in real estate, net 6,938,380 7,022,721 Equity method investments, net - 10,636,544 Other non-current assets 9,581 71,794 Total Non-current Assets 7,055,068 17,748,680 Total Assets $ 7,988,156 $ 20,985,178 LIABILITIES AND (DEFICIT) EQUITY CURRENT LIABILITIES: Accrued professional fees $ 1,583,799 $ 611,462 Accrued research and development fees 153,772 153,772 Accrued payroll liability and compensation 733,669 501,258 Accrued litigation settlement 373,450 373,450 Accrued liabilities and other payables 306,077 434,117 Accrued liabilities and other payables - related parties 100,000 732,916 Operating lease obligation, current portion 69,573 10,709 Advance from pending sale of noncontrolling interest - related party 3,258,078 3,108,106 Derivative liability 125,553 127,545 Stock subscription liability 150,000 - Note payable, net 5,775,061 5,715,447 Convertible note payable, net 2,436,375 2,113,773 Total Current Liabilities 15,065,407 13,882,555 NON-CURRENT LIABILITIES: Operating lease obligation, noncurrent portion 35,022 - Total Non-current Liabilities 35,022 - Total Liabilities 15,100,429 13,882,555 Commitments and Contingencies (Note 15) (DEFICIT) EQUITY: Preferred stock, $ 0.0001 par value; 10,000,000 shares authorized; Series A Convertible Preferred Stock, 0 and 9,000 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively - 9,000,000 Series B Convertible Pr

View Full Filing

View this 10-Q filing on SEC EDGAR